Titanocene dichloride is the organotitanium compound with the formula (η5-C5H5)2TiCl2, commonly abbreviated as Cp2TiCl2. This metallocene is a common reagent in organometallic and organic synthesis. It exists as a bright red solid that slowly hydrolyzes in air. It shows antitumour activity and was the first non-platinum complex to undergo clinical trials as a chemotherapy drug.
Preparation and structure The standard preparations of Cp2TiCl2 start with titanium tetrachloride. The original synthesis by Wilkinson and Birmingham, using sodium cyclopentadienide, is still commonly used:
2 NaC5H5 + TiCl4 → (C5H5)2TiCl2 + 2 NaCl It can also be prepared by using freshly distilled cyclopentadiene rather than its sodium derivative:
2 C5H6 + TiCl4 → (C5H5)2TiCl2 + 2 HCl Focusing on the geometry of the Ti center, Cp2TiCl2 adopts a distorted tetrahedral geometry (counting Cp as a monodentate ligand). The Ti-Cl distance is 2.37 Å and the Cl-Ti-Cl angle is 95°.
Reactions
Halide replacement reactions Cp2TiCl2 serves as a source of Cp2Ti2+. A large range of nucleophiles will displace chloride. With NaSH and with polysulfide salts, one obtains the sulfido derivatives Cp2Ti(SH)2 and Cp2TiS5. The Petasis reagent, Cp2Ti(CH3)2, is prepared from the action of methylmagnesium chloride or methyllithium on Cp2TiCl2. This reagent is useful for the conversion of esters into vinyl ethers. The Tebbe reagent Cp2TiCl(CH2)Al(CH3)2, arises by the action of 2 equivalents Al(CH3)3 on Cp2TiCl2.
Reactions affecting Cp ligands One Cp ligand can be removed from Cp2TiCl2 to give tetrahedral CpTiCl3. This conversion can be effected with TiCl4 or by reaction with SOCl2. The sandwich complex (Cycloheptatrienyl)(cyclopentadienyl)titanium is prepared by treatment of titanocene dichloride with lithium cycloheptatrienyl. Titanocene itself, TiCp2, is so highly reactive that it rearranges into a TiIII hydride dimer and has been the subject of much investigation. This dimer can be trapped by conducting the reduction of titanocene dichloride in the presence of ligands; in the presence of benzene, a fulvalene complex, μ(η5:η5-fulvalene)-di-(μ-hydrido)-bis(η5-cyclopentadienyltitanium), can be prepared and the resulting solvate structurally characterised by X-ray crystallography. The same compound had been reported earlier by a lithium aluminium hydride reduction and sodium amalgam reduction of titanocene dichloride, and studied by 1H NMR prior to its definitive characterisation.
Redox Reduction with zinc gives the dimer of bis(cyclopentadienyl)titanium(III) chloride in a solvent-mediated chemical equilibrium:
Cp2TiCl2 is a precursor to TiII derivatives. Reductions have been investigated using Grignard reagent and alkyl lithium compounds. More conveniently handled reductants include Mg, Al, or Zn. The following syntheses demonstrate some of the compounds that can be generated by reduction of titanocene dichloride in the presence of π acceptor ligands:
Cp2TiCl2 + 2 CO + Mg → Cp2Ti(CO)2 + MgCl2 Cp2TiCl2 + 2 PR3 + Mg → Cp2Ti(PR3)2 + MgCl2 Alkyne derivatives of titanocene have the formula (C5H5)2Ti(C2R2) and the corresponding benzyne complexes are known. One family of derivatives are the titanocyclopentadienes. Rosenthal's reagent, Cp2Ti(η2-Me3SiC≡CSiMe3), can be prepared by this method. Two structures are shown, A and B, which are both resonance contributors to the actual structure of Rosenthal's reagent.
Titanocene equivalents react with alkenyl alkynes followed by carbonylation and hydrolysis to form bicyclic cyclopentadienones, related to the Pauson–Khand reaction. A similar reaction is the reductive cyclization of enones to form the corresponding alcohol in a stereoselective manner. Reduction of titanocene dichloride in the presence of conjugated dienes such as 1,3-butadiene gives η3-allyltitanium complexes. Related reactions occur with diynes. Furthermore, titanocene can catalyze C–C bond metathesis to form asymmetric diynes. Titanocene dichloride as a photoredox catalyst to open epoxides in green light.
Derivatives of (C5Me5)2TiCl2 Many analogues of Cp2TiCl2 are known. Prominent examples are the ring-methylated derivatives (C5H4Me)2TiCl2 and (C5Me5)2TiCl2.
Medicinal research Titanocene dichloride was investigated as an anticancer drug. In fact, it was both the first non-platinum coordination complex and the first metallocene to undergo a clinical trial. Titanocene dichloride itself was ultimately unsuccessful in clinical trials, with its failure attributed to rapid hydrolysis and aggregate formation. This has led to efforts to develop derivatives such as Titanocene Y and Myr-Ti to address these issues - as of 2025, research into these derivatives is still in the preclinical phase.
References
Further reading Payack, J. F.; Hughes, D. L.; Cai, D.; Cottrell, I. F.; Verhoeven, T. R. "Dimethyltitanocene Titanium, bis(η5-2,4-cyclopentadien-1-yl)dimethyl-". Organic Syntheses. 79: 19; Collected Volumes, vol. 10.. Gambarotta, S.; Floriani, C.; Chiesi-Villa, A.; Guastini, C. (1983). "Cyclopentadienyldichlorotitanium(III): a free-radical-like reagent for reducing azo (N:N) multiple bonds in azo and diazo compounds". J. Am. Chem. Soc. 105 (25): 7295–7301. Bibcode:1983JAChS.105.7295G. doi:10.1021/ja00363a015. Chirik, P. J. (2010). "Group 4 Transition Metal Sandwich Complexes: Still Fresh after Almost 60 Years". Organometallics. 29 (7): 1500–1517. doi:10.1021/om100016p.
